Please use this identifier to cite or link to this item:
Title: Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment
Authors: Wong, Clarence T. T.
Rowlands, Dewi K.
Wong, Chi-Hang.
Lo, Theodore W. C.
Nguyen, Giang K. T.
Li, Hoi-Yeung
Tam, James P.
Keywords: DRNTU::Science::Biological sciences
Issue Date: 2012
Source: Wong, C. T. T., Rowlands, D. K., Wong, C.-H., Lo, T. W. C., Nguyen, G. K. T., Li, H.-Y., et al. (2012). Orally Active Peptidic Bradykinin B1 Receptor Antagonists Engineered from a Cyclotide Scaffold for Inflammatory Pain Treatment. Angewandte Chemie International Edition, 51(23), 5620-5624.
Series/Report no.: Angewandte chemie international edition
Abstract: Edible: By grafting natural peptide antagonists onto the cyclotide kalata B1, orally active peptides were engineered, which are potentially useful therapeutics for the treatment of inflammatory pain. For example, the entire loop 6 of kalata B1 was replaced with the peptidic bradykinin B1 receptor antagonist DALK (red in scheme) to obtain the cyclic bradykinin antagonist ckb-kal.
ISSN: 1433-7851
DOI: 10.1002/anie.201200984
Rights: © 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SBS Journal Articles

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.